Comparison of AstraZeneca and sinopharm vaccines as boosters in protection against COVID-19 infection

Khan, 2020, COVID-19: a global challenge with old history, epidemiology and progress so far, Molecules, 26, 39, 10.3390/molecules26010039 van Doorn, 2020, 284 Yang, 2020, COVID-19: a new challenge for human beings, Cell Mol Immunol, 17, 555, 10.1038/s41423-020-0407-x Hu, 2021, Characteristics of SARS-CoV-2 and COVID-19, Nat Rev Microbiol, 19, 141, 10.1038/s41579-020-00459-7 Ren, 2006, Full-length genome sequences of two SARS-like coronaviruses in horseshoe bats and genetic variation analysis, J Gen Virol, 87, 3355, 10.1099/vir.0.82220-0 Umakanthan, 2020, Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19), Postgrad Med, 96, 753 Shchelkanov, 2020, History of investigation and current classification of coronaviruses (Nidovirales: Coronaviridae), Russian Journal of Infection and Immunity, 10, 221, 10.15789/2220-7619-HOI-1412 Malik, 2020, Properties of coronavirus and SARS-CoV-2, Malays J Pathol, 42, 3 V’kovski, 2021, Coronavirus biology and replication: implications for SARS-CoV-2, Nat Rev Microbiol, 19, 155, 10.1038/s41579-020-00468-6 Xu, 2020, High expression of ACE2 receptor of 2019- nCoV on the epithelial cells of oral mucosa, Int J Oral Sci, 12, 1, 10.1038/s41368-020-0074-x Pohl, 2021, SARS-CoV-2 variants reveal features critical for replication in primary human cells, PLoS Biol, 19, 10.1371/journal.pbio.3001006 Unim, 2021, Prevalence of COVID-19-related symptoms by age group, Aging Clin Exp Res, 33, 1145, 10.1007/s40520-021-01809-y Oto, 2021, Predicting the outcome of COVID-19 infection in kidney transplant recipients, BMC Nephrol, 22, 1, 10.1186/s12882-021-02299-w Needham, 2020, Neurological implications of COVID-19 infections, Neurocritical Care, 32, 667, 10.1007/s12028-020-00978-4 Zhao, 2022, The global transmission of new coronavirus variants, Environ Res, 206, 10.1016/j.envres.2021.112240 Cantón, 2021, New variants of SARS-CoV-2, Rev Española Quimioter, 34, 419, 10.37201/req/071.2021 Islam, 2022, New coronavirus variants are creating more challenges to global healthcare system: a brief report on the current knowledge, Clinical Pathology, 15, 10.1177/2632010X221075584 He, 2021, SARS‐CoV‐2 Omicron variant: characteristics and prevention, MedComm, 10.1002/mco2.110 Guo, 2022, SARS-CoV-2 omicron variant: epidemiological features, biological characteristics, and clinical significance, Front Immunol Burki, 2022, Omicron variant and booster COVID-19 vaccines, Lancet Respir Med, 10, e17, 10.1016/S2213-2600(21)00559-2 Kassaw, 2021, Trust about corona vaccine among health professionals working at Dilla University referral hospital, 2021, Vaccine X, 9, 10.1016/j.jvacx.2021.100120 Zhou, 2021, Research progress and challenges to coronavirus vaccine development, J Med Virol, 93, 741, 10.1002/jmv.26517 Saeed, 2021, Side effects and perceptions following Sinopharm COVID-19 vaccination, Int J Infect Dis, 111, 219, 10.1016/j.ijid.2021.08.013 Zhang, 2021, Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial, Lancet Infect Dis, 21, 181, 10.1016/S1473-3099(20)30843-4 Chi, 2017, DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice, Vaccine, 35, 2069, 10.1016/j.vaccine.2017.02.063 Smith, 2020, Immunogenicity of a DNA vaccine candidate for COVID-19, Nat Commun, 11, 1, 10.1038/s41467-020-16505-0 Silveira, 2021, DNA vaccines against COVID-19: perspectives and challenges, Life Sci, 267, 10.1016/j.lfs.2020.118919 Xia, 2020, Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials, JAMA, 324, 951, 10.1001/jama.2020.15543 Almufty, 2021, Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study, Diabetes Metabol Syndr: Clin Res Rev, 15, 10.1016/j.dsx.2021.102207 Whitaker, 2022, Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response among individuals in clinical risk groups, J Infect, 10.1016/j.jinf.2021.12.044 Ashraf, 2021, COVID-19 vaccines (revisited) and oral- mucosal vector system as a potential vaccine platform, Vaccines, 9, 171, 10.3390/vaccines9020171 Cross, 2021, Who funded the research behind the Oxford–AstraZeneca COVID-19 vaccine?, BMJ global health, 6, 10.1136/bmjgh-2021-007321 Ghiasi, 2021, Efficacy and side effects of Sputnik V, Sinopharm and AstraZeneca vaccines to stop COVID-19; a review and discussion, Immunopathologia Persa, 7, 31, 10.34172/ipp.2021.31 Sønderskov, 2021, Sustained COVID-19 vaccine willingness after safety concerns over the Oxford-AstraZeneca vaccine, Dan Med J, 68 Solomon, 2021, COVID-19 vaccine: side effects after the first dose of the Oxford AstraZeneca vaccine among health professionals in low-income country: Ethiopia, J Multidiscip Healthc, 14, 2577, 10.2147/JMDH.S331140 Rashedi, 2022, COVID‐19 vaccines mix‐and‐match: the concept, the efficacy and the doubts, J Med Virol, 94, 1294, 10.1002/jmv.27463 Mallapaty, 2021, WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic, Nature, 594, 161, 10.1038/d41586-021-01497-8 Hart, 2022, COVID-19 vaccine boosters in the Asia-Pacific region in the context of Omicron, The Lancet Regional Health–Western Pacific, 10.1016/j.lanwpc.2022.100404 Zhu, 2020, Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial, Lancet, 395, 1845, 10.1016/S0140-6736(20)31208-3 Voysey, 2021, Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV- 2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK, Lancet, 397, 99, 10.1016/S0140-6736(20)32661-1 Chung, 2021, Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study, BMJ, 374 Ramasamy, 2020, Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial, Lancet, 396, 1979, 10.1016/S0140-6736(20)32466-1 Alqassieh, 2021, Pfizer-BioNTech and Sinopharm: a comparative study on post- vaccination antibody titers, Vaccines, 9, 1223, 10.3390/vaccines9111223 Hodgson, 2021, What defines an efficacious COVID -19 vaccine ? A revoew of the challenges assessing the clinical efficacy of vaccines against SARS – COV – 2, Lancet Infect Dis., 21, 26, 10.1016/S1473-3099(20)30773-8 Mattiuzzi, 2022, Primary COVID-19 vaccine cycle and booster doses efficacy: analysis of Italian nationwide vaccination campaign, Eur J Publ Health, 10.1093/eurpub/ckab220 Lipsitch, 2020, Understanding COVID – 19 vaccine efficacy, Science, 370, 763, 10.1126/science.abe5938 Oguh, 2020, Structure and function of COVID -19 encode proteins in the transcription and replication mechanism with its preventive measures and propose efficacy treatments: a critical systematic review, Asian J Immunol, 3, 15 Kissler, 2021, Viral dynamics of SARS-CoV-2 variants in vaccinated and unvaccinated persons, N Engl J Med, 385, 2489, 10.1056/NEJMc2102507 Zhu, 2020, Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial, Lancet, 396, 479, 10.1016/S0140-6736(20)31605-6 Voysey, 2021, Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK (vol 397, pg 99, 2021), Lancet, 98 Abu -Hammad, 2021, Sidw effects reported by Jordanian healthcare workers who received COVID -19 vaccines, Vaccines, 577, 10.3390/vaccines9060577 Wise J. Covid -19 European countries suspend use of Oxford – AstraZeneca vaccine after reports of blood clots. Ramasamy, 2020, Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial, Lancet, 396, 1979, 10.1016/S0140-6736(20)32466-1 Rodriguez‐Coira, 2021, SARS‐CoV‐2 candidate vaccines‐composition, mechanisms of action and stages of clinical development, Allergy, 76, 1922, 10.1111/all.14714 Finberg RW . No, vaccine side effects don't tell you how well your immune system will protect you from COVID -19 . . . Kahn, 2020, Opinion: for now, its unethical to use human challenge studies for SARS – coV – 2 vaccine development, Proc Natl Acad Sci USA, 117, 28538, 10.1073/pnas.2021189117 Falsey, 2021, SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3, N Engl J Med, 385, 1627, 10.1056/NEJMc2113468 Shen, 2020, Prevention and control of COVID – 19 in public transportation : experience from China, Environ Pollut